MBRX - Wutah dodolan taun lumaku moleculin.com

Logo grafis Moleculin Biotech (MBRX)

Moleculin Biotech, Inc. (MBRX) creates unique molecules to combat tumor resistance, ensuring high margins. The company relies on contract manufacturing and outsourced trial management. The year-over-year sales trend over the last 12 months visualizes revenue dynamics, where 0.00 serves as the base parameter value. The business is resilient to macro cycles, expanding through the commercialization of innovations and clinical trial phases.

Wutah dodolan YoY sajrone rolas wulan kepungkur Moleculin Biotech, Inc. (MBRX): kanggo periode 11.02.2024 - 18.11.2026

Ringkesan rincian data analitis moleculin.com (MBRX)

- rega saiki lan proyeksi nilai saham:
Analisis kabeh metrik perusahaan:MBRX - Moleculin Biotech
Produk seri Moleculin Biotech, Inc.

Year-over-year (TTM) sales growth measures the percentage change in annual revenue over a rolling period in continuous dynamics. This metric is calculated as the difference between current aggregate income and the equivalent window from the previous year, reflecting the business's sensitivity to market demand. By analyzing the trajectory of YoY sales volume growth over a rolling year, an investor assesses commercialization efficiency. For Moleculin Biotech, Inc. (MBRX), this trend depends directly on the success of the Phase 2 trials for annamycin.